These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7081976)

  • 1. High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme.
    Cisani G; Varaldo PE; Grazi G; Soro O
    Antimicrob Agents Chemother; 1982 Apr; 21(4):531-5. PubMed ID: 7081976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Staphylococcus aureus with a fluorescence in situ hybridization that does not require lysostaphin.
    Lawson TS; Connally RE; Iredell JR; Vemulpad S; Piper JA
    J Clin Lab Anal; 2011; 25(2):142-7. PubMed ID: 21438009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production.
    Schlievert PM; Kilgore SH; Beck LA; Yoshida T; Klingelhutz AJ; Leung DYM
    mSphere; 2023 Feb; 8(1):e0057622. PubMed ID: 36598227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
    Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
    J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].
    Jin J; Zhou H; Cui ZC; Wang L; Luo PF; Ji SZ; Hu XY; Ma B; Wang GY; Zhu SH; Xia ZF
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):225-232. PubMed ID: 29690741
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus.
    Polak J; Della Latta P; Blackburn P
    Diagn Microbiol Infect Dis; 1993; 17(4):265-70. PubMed ID: 8112040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM; Kokai-Kun JF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S; Coote PJ
    J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity.
    Severance PJ; Kauffman CA; Sheagren JN
    J Clin Microbiol; 1980 Jun; 11(6):724-7. PubMed ID: 7430338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysostaphin disk test for routine presumptive identification of staphylococci.
    Poutrel B; Caffin JP
    J Clin Microbiol; 1981 Jun; 13(6):1023-5. PubMed ID: 7019233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of BiTek agar on lysostaphin susceptibility of staphylococci.
    Langlois BE; Dawson K; Akers K
    J Clin Microbiol; 1990 Nov; 28(11):2568-9. PubMed ID: 2254432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
    Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cloning of lysozyme and lysostaphin genes of Staphylococcus aureus and their expression in Bacillus subtilis cells].
    Zhdanova LV; Romanova IuM; Bondarenko VM; Konstantinova GE; Shevelev AB
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (4):3-6. PubMed ID: 11569257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP; Gemmell CG; Coote PJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMPARATIVE IN VITRO ACTIVITIES OF LYSOSTAPHIN AND OTHER ANTISTAPHYLOCOCCAL ANTIBIOTICS ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS.
    HARRISON EF; CROPP CB
    Appl Microbiol; 1965 Mar; 13(2):212-5. PubMed ID: 14325881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal synergy of lysostaphin in combination with antimicrobial peptides.
    Desbois AP; Coote PJ
    Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):1015-21. PubMed ID: 21311938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the lysostaphin-susceptibility test for the classification of staphylococci.
    Heddaeus H; Heczko PB; Pulverer G
    J Med Microbiol; 1979 Feb; 12(1):9-15. PubMed ID: 430548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic applications of lysostaphin against Staphylococcus aureus.
    Jayakumar J; Kumar VA; Biswas L; Biswas R
    J Appl Microbiol; 2021 Sep; 131(3):1072-1082. PubMed ID: 33382154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis.
    McCormick CC; Dajcs JJ; Reed JM; Marquart ME; O'Callaghan RJ
    Curr Eye Res; 2006 Mar; 31(3):225-30. PubMed ID: 16531279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.